Discovery of Novel Antidepressants and Anxiolytics

Dear Colleagues,

Depression and anxiety are common psychiatric illnesses of global impact. Novel therapeutics are desirable among patients who continue to experience delayed or low responses, adverse effects, and unsatisfactory remission rates with the available drugs. Understanding the complex neurobiology of these psychiatric illnesses is among the prerequisites to the comprehensive assessments of biomarkers or molecular targets, pharmacokinetics, and the clinical efficacy, safety, acceptability, and tolerability of novel antidepressants and anxiolytics. This Special Issue accepts contributions covering new compound/drug candidates, research results, current understandings of depression and anxiety, and updates on pharmacotherapy options and other related topics.

Prof. Dr. James Oluwagbamigbe Fajemiroye
Dr. Gunnar P. H. Dietz
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• biomarkers
• depression
• anxiety
• anxiolytics
• antidepressants
• preclinical or clinical overview
• experimental data
• adverse effects
• pharmacotherapy options
• novel drugs